 |
|
Poster
Presentations-Session II |
|
|
|
PHARMACOECONOMIC
& OUTCOMES RESEARCH
METHODOLOGY STUDIES |
| |
General and Clinical
Studies |
 |
| PMD1 |
A NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER
NEEDED TO TREAT REGARDING VARIABLE RELATIVE RISK REDUCTION
Aino H, Yanagisawa S, Cai L, Inoue H, Nakajo K, Kamae I, Kobe
University, Kobe, Japan |
| PMD2 |
METHODOLOGICAL DESIGNS & OUTCOMES OF
EFFECTIVENESS STUDIES – A LITERATURE REVIEW
Chau D1, Shane LG2, Redding L3, Han D4, Rauch B1, Lee M5,
Potvin K6, 1Amgen Canada Inc, Mississauga, ON, Canada;
2GlaxoSmithKline Inc, Mississauga, ON, Canada; 3Hoffmann-La Roche
Limited, Mississauga, ON, Canada; 4Wyeth Pharmaceuticals, Markham, ON,
Canada; 5AstraZeneca Canada Inc, Mississauga, ON, Canada; 6Canada's
Research-Based Pharmaceutical Companies, Ottawa, ON, Canada |
| PMD3 |
INSTRUMENT STRENGTH AND PERFORMANCE OF A
PARAMETRIC LATENT INDEX MODEL IN ESTIMATING AVERAGE TREATMENT EFFECT
(ATE)
Wu EQ1, Johnson KA2, Nichol MB2, 1Analysis Group/Economics,
Boston, MA, USA; 2University of Southern California, Los Angeles, CA,
USA |
| PMD4 |
PERFORMANCE OF TWO CONDITIONAL EXPECTATION
METHODS UNDER UNOBSERVED SELECTION BIAS
Wu EQ1, Nichol MB2, Johnson KA2, 1Analysis Group/Economics,
Boston, MA, USA; 2University of Southern California, Los Angeles, CA,
USA |
| PMD5 |
IMPROVING REPORTS OF PRO DATA TO SUPPORT AN
EFFECTIVENESS CLAIM
Marquis P1, Piault E1, Abetz L2, Arnould B3, 1Mapi Values,
Boston, MA, USA; 2Mapi Values, Cheshire, UK; 3Mapi Values, Lyon,
France |
| PMD6 |
ESTIMATING THE TRAJECTORY-ADJUSTED IMPACT OF
ACUTE EVENTS ON PATIENT-REPORTED OUTCOMES
Weinfurt KP1, Li Y1, Castel LD1, Glendenning A2, Schulman KA1,
1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis
Pharmaceuticals, East Hanover, NJ, USA |
| PMD7 |
THE CONGRUENCE OF SELF-REPORT WITH OTHER
MEASURES OF MEDICATION ADHERENCE: A SUMMARY OF THE LITERATURE
Garber M, Nau D, Erickson S, University of Michigan, Ann Arbor,
MI, USA |
| PMD8 |
PATIENT SAFETY RESEARCH: A DISCUSSION OF
TERMINOLOGY, PROPOSED DEFINITIONS, AND A CONCEPTUAL MODEL FOR ADVERSE
EVENTS INVOLVING MEDICAL DEVICES
Bright RA1, Kaye R1, Samore MH2, 1Food and Drug Administration,
Rockville, MD, USA; 2University of Utah, Salt Lake City, MD, USA
|
| PMD9 |
INTERNET-BASED PATIENT REGISTRIES IN COMMUNITY
PRACTICE
Sherwood AD1, Walt JG2, 1MedNet Solutions, Minnetonka, MN, USA;
2Allergan, Inc, Irvine, CA, USA |
| PMD10 |
EVALUATING RETROSPECTIVE STUDY POSTERS PRESENTED
AT THE ISPOR 7TH ANNUAL CONFERENCE
Patel VD, Setyawan J, Nichol MB, University of Southern
California, Los Angeles, CA, USA |
| PMD11 |
BEST PRACTICES: EVALUATING MODELING RESEARCH AT
ISPOR USING BMJ AND ISPOR GUIDELINES
Setyawan J, Patel V, Nichol MB, University of Southern
California, Los Angeles, CA, USA |
| PMD12 |
PHARMACOEPIDEMIOLGY: A REVIEW OF ITS EMERGING
ROLE IN OUTCOMES RESEARCH
Richard L, Heron Evidence Development Ltd, Stevenage,
Hertfordshire, UK |
| PMD13 |
OPTIMIZING CLINICAL EFFECTIVENESS THROUGH
ACTUARIAL MODELING IN HOSPITALS
Vogenberg FR1, Weinberg R1, Lichtig L1, Liebeskind D1, Larrat
EP2, 1Aon Consulting, Wellesley, MA, USA; 2University of Rhode Island
College of Pharmacy, Kingston, RI, USA |
| |
Economic
Studies |
|
|
| PMD14 |
DEVELOPING A HEALTH ECONOMIC EVALUATION DATABASE
IN JAPAN: JEED PROJECT
Fukuda T, Tsutani K, Kobayashi Y, University of Tokyo, Bunkyo,
Tokyo, Japan |
| PMD15 |
DO DIFFERENCES AMONG COST-EFFECTIVENESS ANALYSIS
GUIDELINE RECOMMENDATIONS AFFECT POLICY CONCLUSIONS?
Schackman BR1, Gold HT1, Stone PW2, Neumann PJ3, 1Weill
Medical College of Cornell University, New York, NY, USA; 2Columbia
University School of Nursing, New York, NY, USA; 3Harvard University,
Boston, MA, USA |
| PMD16 |
FACILITATING USER INTERACTION WITH
PHARMACOECONOMIC MODELS: MODEL-IT®
Caro J, Magno L, Ward AJ, Caro Research Institute, Concord, MA, USA
|
| PMD17 |
ARE PUBLISHED COST-UTILITY ANALYSES IMPROVING?
Neumann PJ1, Olchanski NV1, Rosen AB1, Greenberg D1, Chapman
R1, Stone P2, Nadai J1, 1Harvard University, Boston, MA, USA;
2Columbia University, New York, NY, USA |
| PMD18 |
ECONOMIC EVALUATION IN CLINIC TRIALS:
CALCULATING HOSPITALIZATION COSTS FROM CLINIC TRIAL DATA
Henk HJ, University of Wisconsin, Madison, WI, USA |
| PMD19 |
COMMUNITY OR PATIENT PREFERENCES FOR
COST-UTILITY ANALYSES: DOES IT MATTER?
Furlong W1, Oldridge N2, Perkins A3, Feeny D4, Torrance GW1,
1McMaster University, Hamilton, ON, Canada; 2Indiana University,
Indianapolis, IN, USA; 3Regenstrief Institute for Health Care,
Indianapolis, IN, USA; 4University of Alberta, Edmonton, AB, Canada
|
| PMD20 |
SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES
OF MEDICAL TECHNOLOGY IN THAILAND
Chaiyakunapruk N1, Chaikhiendee J1, Jongrungrotsakul N1,
Thadapark U2, 1Naresuan University, Phitsanulok, Thailand; 2Chiangmai
University, Chiangmai, Thailand |
| PMD21 |
A RELIABLE AND ROBUST ALGORITHM TO DETERMINE IN-
HOSPITAL LENGTH OF STAY AND READMISSIONS USING RAMQ
Tahami Monfared AA, LeLorier J, Centre Hospitalier de
l'Université de Montréal, Campus Hôtel Dieu, Montreal, QC, Canada
|
| PMD22 |
AN INVESTIGATION OF PATIENT HETEROGENEITY AND
THE POTENTIAL FOR BIAS IN MODELLING STUDIES: AN EXAMPLE USING A MARKOV
MODEL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Briggs AH1, Spencer MD2, 1University of Oxford, Oxford, UK;
2GlaxoSmithkline, Greenford, Middlesex, UK |
| PMD23 |
IS MARKOV CHAIN/DECISION TREE APPROACH BETTER
THAN COST FUNCTION APPROACH IN MODELING THE PHARMA-
CEUTICAL COSTS FOR ATTENTION DEFICIT/HYPERACTIVITY
DISORDER? AN EMPIRICAL STUDY BASED ON A LARGE CLAIM DATABASE
Sun P, Swindle R, Eli Lilly and Company, Indianapolis, IN, USA
|
| PMD24 |
PROBABILISTIC SENSITIVITY ANALYSES: COMMONLY
RECOMMENDED, UNCOMMONLY PERFORMED
Rocchi A, Chin W, Axia Research, Hamilton, ON, Canada |
| PMD25 |
INCREASING PUBMED YIELD FOR PHARMACOECONOMIC
RESEARCH USING ITERATIVE SEARCH STRATEGIES
Frame D1, Klawansky S2, 1MetaWorks Inc, Medford, MA, USA;
2Harvard School of Public Health, Boston, MA, USA |
| PMD26 |
ECONOMIC AND OUTCOMES RESEARCH IN THE REAL
WORLD: EVALUATION OF ITS RELEVANCE
Crawford B1, Baron-Papillon F2, Evans C1, Horowitz-Mehler N1,
1Mapi Values, Boston, MA, USA; 2Mapi Values, Lyon, France |
| PMD27 |
DO PHARMACOECONOMIC FELLOWSHIP PROGRAMS PROVIDE
THE SKILLS NECESSARY FOR TODAY’S WORK ENVIRONMENT?
Maio V, Lofland JH, Thomas Jefferson University, Philadelphia,
PA, USA |
| |
Quality of
Life/Preference Studies |
|
|
| PMD28 |
ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP –
TRANSLATION AND CULTURAL ADAPTATION: DEVELOPMENT OF PRINCIPLES OF BEST
PRACTICE
Wild DJ1, Grove A1, Martin M2, Eremenco S3, 1Oxford Outcomes
Ltd, Oxford, UK; 2Health Research Associates, Mountlake Terrace, WA,
USA; 3Evanston Northwestern Healthcare, Evanston, IL, USA |
| PMD29 |
DATABASES AND INSTRUCTION MANUALS: VALUABLE
TOOLS TO BETTER LEARN ABOUT THE WHQ, PGWBI AND MLHF QUESTIONNAIRES –
THE INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD)
PROGRAMME
Mouly M1, Fayol-Paget C2, Lobo-Luppi L1, 1for the IQOD Group,
Mapi Research Institute, Lyon, France; 2Mapi SA, Lyon, France |
| PMD30 |
AN IMPROVED MODEL TO CALCULATE UTILITY SCORES
FROM SF-36 DATA
McEwan P, Morrissey M, Currie CJ, Cardiff Research Consortium,
Cardiff, Wales, UK |
| PMD31 |
ASSESSING FUNCTIONAL STATUS IN CHILDREN: A
REVIEW OF THE CHILDHOOD HAQ FOR NON-ARTHRITIS INDICATIONS
Tran KT1, Stephens JM1, Gold KF1, Kimura A2, Pashos CL3, 1Abt
Associates Clinical Trials, Bethesda, MD, USA; 2Transkaryotic
Therapies Inc, Cambridge, MA, USA; 3Abt Associates Clinical Trials,
Cambridge, MA, USA |
| PMD32 |
COMPARING SHORT FORM 6D, STANDARD GAMBLE, AND
HEALTH UTILITIES INDEX MARK 2 AND MARK 3 UTILITY SCORES: RESULTS FROM
TOTAL HIP ARTHROPLASTY PATIENTS
Feeny DH1, Wu L2, Eng K1, 1Institute of Health Economics,
Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada
|
| PMD33 |
RELATIONSHIP OF QUALITY OF LIFE DOMAINS TO
PREFERENCE-BASED MEASURES OF QUALITY OF LIFE
Miller LAN1, Singer ME2, 1West Virginia University School of
Pharmacy, Morgantown, WV, USA; 2Case Western Reserve University School
of Medicine, Cleveland, OH, USA |
| PMD34 |
COMPARISON OF SF-36 SUMMARY AND PREFERENCE-BASED
UTILITY SCORES ACROSS GROUPS DIFFERING IN DISEASE SEVERITY: RESULTS
FROM THE MEDICARE HEALTH OUTCOMES SURVEY
Ware JE1, Bierman AS2, Gandek B3, Sinclair SJ3, Lawrence WF2,
1QualityMetric Incorporated, Lincoln, RI, USA; 2Agency for Healthcare
Research and Quality, Rockville, MD, USA; 3Health Assessment Lab,
Boston, MA, USA |
| PMD35 |
QUALITY OF LIFE DIFFERENCES IN OLDER ADULTS WITH
VARIED COMORBID CONDITIONS
Martin ML, Bushnell DM, Budhiarso I, Health
Research Associates, Inc (HRA), Seattle, WA, USA |
| PMD36 |
JUSTIFYING THE DEVELOPMENT OF A LAY PANEL TO
PRODUCE UTILITIES FOR USE IN HEALTH TECHNOLOGY ASSESSMENTS (HTAS):
REVIEW OF CURRENT ISSUES, AND VIEWS OF TECHNOLOGY APPRAISAL COMMITTEE
MEMBERS
Fry AM1, Round A1, Stein K1, Brazier J2, Milne R3, 1Peninsula
Medical School, Exeter, Devon, UK; 2The University of Sheffield,
Sheffield, UK; 3University of Southampton, Southampton, UK |
| PMD37 |
IMPACT OF SOCIODEMOGRAPHICS ON QUALITY OF LIFE
DOMAINS
Miller LAN1, Singer ME2, 1West Virginia University School of
Pharmacy, Morgantown, WV, USA; 2Case Western Reserve University School
of Medicine, Cleveland, OH, USA |
|
CARDIOVASCULAR DISEASES/DISORDERS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PCV1 |
VALIDATION OF EQUATIONS USED TO PREDICT WARFARIN
DOSING DECISIONS
Shermock KM1, Connor JT2, Thomas N3, Fink J2, Bragg L2, 1The
Johns Hopkins Hospital, Baltimore, MD, USA; 2The Cleveland Clinic
Foundation, Cleveland, OH, USA; 3Brigham Young University, Provo, UT,
USA |
| PCV2 |
TELEMONITORS REDUCE HOSPITAL AND ER ADMISSIONS
FOR HOMEBOUND CONGESTIVE HEART FAILURE (CHF) PATIENTS
Schabert VF, Johann JS, Davis N, Strategic Healthcare Programs,
Santa Barbara, CA, USA |
| PCV3 |
PREDICTORS OF ADHERENCE TO ANTIHYPERTENSIVES IN
A MANAGED CARE POPULATION
D'Angio R1, Shah BM2, Gupchup GV2, Sabrsula S3, 1Pfizer Inc,
Albuquerque, NM, USA; 2The University of New Mexico, Albuquerque, NM,
USA; 3Firstcare, Austin, TX, USA |
| PCV4 |
THE EFFECT OF STATIN DOSE ON ATTAINMENT OF
TARGET LDL-C LEVELS
Al-Zakwani IS1, Bullano MF1, Willey VJ1, Graham L2, Corbelli
JC3, 1Health Core, Inc, Newark, DE, USA; 2Pfizer, New York, NY, USA;
3Buffalo Cardiology and Pulmonary Associates, Williamsville,
NY, USA |
| PCV5 |
CLINICAL EFFECTIVENESS OF AMLODIPINE ON SYSTOLIC
BLOOD PRESSURE AS MONOTHERAPY AND IN COMBINATION
Roberts C1, McLaughlin T2, Tang SS3, Battleman DS3, 1NDCHealth,
Yardley, PA, USA; 2NDCHealth, Phoenix, AZ, USA; 3Pfizer, Inc, New
York, NY, USA |
| PCV6 |
A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT
OF PULMONARY ARTERIAL HYPERTENSION
Richard L, Heron Evidence Development Ltd, Stevenage,
Hertfordshire, UK |
| PCV7 |
TREATMENT OF PRIMARY PULMONARY HYPERTENSION (PPH):
A COST-UTILITY ANALYSIS
Tano BD1, Sood N1, Hoffmann S2, Pathak D2, 1Ohio State
University Medical Center, Columbus, OH, USA; 2The Ohio State
University, Columbus, OH, USA |
| PCV8 |
ESTIMATING POPULATION BLOOD PRESSURE CONTROL
AMONG US HYPERTENSIVE PATIENTS
Yuan Y1, Chen R1, L'Italien G1, Karaniewsky R2, 1Bristol-Myers
Squibb, Princeton, NJ, USA; 2Bristol-Myers Squibb, Plainsboro, NJ, USA
|
| PCV9 |
META-ANALYSIS OF STATINS IN THE LOWERING OF
LOW-DENSITY LIPOPROTEIN CHOLESTEROL TO EUROPEAN ATHEROSCLEROSIS
SOCIETY TARGET USING ROSUVASTATIN AS A COMMON COMPARATOR
Morrell J1, Edwards S2, 1Fitznells Manor Surgery, Ewell,
Surrey, UK; 2AstraZeneca UK Ltd, Luton, Bedfordshire, UK |
| PCV10 |
DEFINING OUTCOMES IN STUDIES OF BLEEDING
MORBIDITY ASSOCIATED WITH ANTICOAGULATION THERAPY
Ofori BD1, Davey PG1, Goudie B2, Timoney A3, 1University
of Dundee, Dundee, UK; 2Westgate Health Centre, Dundee, UK; 3Tayside
Health Board, Dundee, UK |
| PCV11 |
EFFECTIVENESS OF CLINICAL PATHWAYS FOR PATIENTS
WITH HEART FAILURE
Panella M, Marchisio S, University of Eastern Piedmont “A.
Avogadro, Novara, Italy |
| PCV12 |
ACHIEVEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET BY
HYPERCHOLESTEROLAEMIC PATIENTS RECEIVING ROSUVASTATIN COMPARED TO
ATORVASTATIN, PRAVASTATIN OR SIMVASTATIN: AN EVIDENCE-BASED MEDICINE
APPROACH
Morrell J1, Edwards S2, 1Fitznells Manor Surgery, Ewell,
Surrey, UK; 2AstraZeneca UK Ltd, Luton, Bedfordshire, UK |
| PCV13 |
ENOXAPARIN USE IN PATIENTS WITH MECHANICAL HEART VALVES REQUIRING
BRIDGING THERAPY FOR SUBTHERAPEUTIC CHRONIC ORAL ANTICOAGULATION
Cross LB1, Hamann GL2, Campbell JD2, Dorko CS2, Bailey LE2,
1University of Tennessee Health Science Center, Memphis, TN, USA;
2Regional Medical Center, Memphis, TN, USA |
| PCV14 |
RACIAL VARIATION IN THE UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS:
AN ANALYSIS OF 1998 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Yang Y, Waters TM, The University of Tennessee, Memphis, TN,
USA |
| PCV15 |
WITHDRAWN |
| PCV16 |
SMOKING DEPENDENCY: AUDIT CARRIED OUT AMONG THE UNDER 25 GROUP
Taïeb C, Myon E, Pierre Fabre SA, Boulogne Billancourt, France
|
| PCV17 |
RELATIONSHIP BETWEEN PATIENT BELIEFS ABOUT MEDICATION AND
SELF-REPORTED MEDICATION ADHERENCE SIX MONTHS AFTER DISCHARGE FOR
ACUTE CORONARY SYNDROMES
Stafkey DR, Erickson SR, Kline-Rogers EM, Smith DE, Cooper JV,
Chang A, Eagel KA, University of Michigan, Ann Arbor, MI, USA |
| PCV18 |
A
CONFIRMATORY FACTOR ANALYSIS EVALUATION OF THE CORONARY HEART DISEASE
RISK FACTORS OF METABOLIC
SYNDROME AND THE EFFECTIVENESS OF THE CURRENT ATP III GUIDELINES FOR
IDENTIFICATION
Novak S, Stapleton LM, Litaker JR, Lawson KA, University of
Texas at Austin, Austin, TX, USA |
| PCV19 |
SMOKING CESSATION: RELEVANCE IN THE UNDER 25 GROUP
Taïeb C, Myon E, Pierre Fabre SA, Boulogne Billancourt, France
|
| PCV20 |
DYSLIPIDEMIA PATTERNS AMONG HIGH RISK MEMBERS OF A MANAGED CARE
ORGANIZATION
Lewis BE1, McDonough K2, Pethick N2, O'Donnell JC2,
1Astra-Zeneca, Worcester, MA, USA; 2Astrazeneca, Wilmington, DE, USA
|
| PCV21 |
TREATMENT PATTERNS AMONG NEWLY DIAGNOSED CORONARY HEART DISEASE
PATIENTS: CORRELATES OF LIPID
MANAGEMENT
Watson-Heidari T1, Ershoff D2, Stacy J1, O'Donnell J2, Schmaltz
S1, 1Humana Inc, Louisville, KY, USA; 2AstraZeneca LP, Wayne, PA, USA |
| PCV22 |
DISEASE MANAGEMENT REDUCES HEALTHCARE DISPARITIES IN HEART FAILURE
PATIENTS
Walker DR, Landis DL, O'Leary JS, Vance RP, CorSolutions,
Buffalo Grove, IL, USA |
| |
Economic Outcomes
Presentations |
|
|
| PCV23 |
A
COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION
Hartzema AG, Winterstein AG, Kwon SY, University of Florida,
Gainesville, FL, USA |
| PCV24 |
RATES OF HOSPITALIZATIONS FOLLOWING ATHEROTHROMBOTIC STROKE AND
ASSOCIATED COSTS
Caro J1, Migliaccio-Walle K1, Ishak K2, O'Brien J1, 1Caro
Research Institute, Concord, MA, USA; 2Caro Research Institute, Dorval,
QC, Canada |
| PCV25 |
AN
INVESTIGATION OF THE CARE NEEDS AFTER ACUTE ISCHEMIC STROKE: AN
ANALYSIS OF THE DATA COLLECTED IN THE ERLANGEN STROKE PROJECT
Ward AJ1, Payne KA2, Caro J1, Heuschmann PL3, Kolominsky-Rabas
P3, 1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Montreal, QC, Canada; 3University of Erlangen, Erlangen,
Germany |
| PCV26 |
RATES OF VENOUS THROMBOEMBOLISM AND ASSOCIATED INPATIENT HEALTHCARE
RESOURCE USE AMONG PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY IN AN
INTEGRATED DELIVERY SYSTEM
Boulanger L1, Hauch O2, Wygant G2, Dixon D1, Friedman M3, Menzin J1,
1Boston Health Economics, Inc., Waltham, MA, USA; 2AstraZeneca, L.P,
Wilmington, DE, USA |
| PCV27 |
THE
IMPACT OF ATHEROTHROMBOTIC EVENTS ON RESOURCE USE AND COST IN PATIENTS
WITH PERIPHERAL ARTERIAL
DISEASE
Caro J1, Migliaccio-Walle K1, Ishak K2, O'Brien J1, 1Caro
Research Institute, Concord, MA, USA; 2Caro Research Institute, Dorval,
QC, Canada |
| PCV28 |
ECONOMIC OUTCOMES ASSOCIATED WITH CHOICE OF TREATMENT IN DEEP VENOUS
THROMBOSIS AND PULMONARY EMBOLISM
Knight KK1, Wong JY1, Hauch O2, Aguilar D1, Reynolds M2, Wygant
G2, Ofman JJ1, 1Zynx Health Incorporated, Beverly Hills, CA, USA;
2AstraZeneca, LP, Wilmington, DE, USA |
| PCV29 |
HEALTH SERVICE UTILIZATION, COSTS AND OUTCOMES OF PATIENTS WHO USED
DIFFERENT TYPES OF CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION
Liu X, Yu W, WellPoint Pharmacy Management, West Hills, CA, USA
|
| PCV30 |
ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE
TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY: A
COST-MINIMIZATION ANALYISIS BASED ON LIFE STUDY
Chevreul K1, Durand-Zaleski I2, Souchet T3, 1Robert Debré Hospital,
Paris, France; 2Hôpital Henri Mondor, Paris, France; 3Merck Sharp &
Dohme - Chibret, Paris, France |
| PCV31 |
ECONOMIC IMPACT OF UNCONTROLLED HYPERTENSION AMONG NSAID USERS
Shaya FT1, Mullins CD1, Wong W2, Johnson W3, Saunders E3,
1University of Maryland School of Pharmacy, Baltimore, MD, USA;
2CareFirst BlueCross BlueShield, Baltimore, MD, USA; 3University of
Maryland School of Medicine, Baltimore, MD, USA |
| PCV32 |
EXCESS COSTS FOR SINGLE AGENT MEDICATION TREATMENT OF HYPERTENSION:
1999 DATA FROM THE NEW YORK STATE MEDICAID CLAIMS DATABASE
Cosler LE, Hamilton RA, Clause S, Albany College of Pharmacy,
Albany, NY, USA |
| PCV33 |
COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE
NIACIN TO ACHIEVE LDL AND HDL GOAL USING NHANES DATA
Armstrong EP, Zachry III WM, Malone DC, University of Arizona,
Tucson, AZ, USA |
| PCV34 |
DETERMINANTS OF COST EFFECTIVENESS IN CLINICAL GUIDELINES FOR
CARDIOVASCULAR PROPHYLAXIS WITH STATINS
Milne RJ, Gamble GD, University of Auckland, Auckland, New
Zealand |
| PCV35 |
COST
EFFECTIVENESS ANALYSIS OF HMG-COA REDUCTASE INHIBITORS IN A MEDICAID
POPULATION
MacLean EA, Moffitt CM, Pfizer, Inc, Wakefield, RI, USA
|
| PCV36 |
COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR
RISK PATIENTS: AN ECONOMIC
EVALUATION BASED ON THE HEART PROTECTION STUDY
Fagnani F1, Lafuma A2, Souchet T3, 1CEMKA, Bourg la
Reine, France; 2CEMKA-EVAL, Bourg La Reine, France; 3Merck Sharp &
Dohme - Chibret, Paris, France |
| PCV37 |
BASELINE PREDICTORS OF ONE-YEAR COSTS AFTER ACUTE MYOCARDIAL
INFARCTION IN THE ELDERLY
Liao L1, Bundorf MK2, Kauf T3, Schulman K1, Whellan D4, Jollis
J1, 1Duke University Medical Center, Durham, NC, USA; 2Stanford
University, Stanford, CA, USA; 3Duke University, Durham, NC, USA;
4Duke Clinical Research Institute, Durham, NC, USA |
| PCV38 |
A
COST AND COST-EFFECTIVENESS (CE) ANALYSIS OF ANGIOTENSIN CONVERTING
ENZYME (ACE) INHIBITOR TRANDOLAPRIL IN THE TREATMENT OF POST
INFARCTION IN THE US
Lilliu H1, Le Pen C1, Lamiraud K1, Wittenberg W2, 1Clp-santé,
Paris, France; 2Abbott GmbH &Co KG, Ludwigshafen, Germany |
| PCV39 |
IMPACT OF ANEMIA ON HF HOSPITAL LENGTH OF STAY: LONGITUDINAL ANALYSIS
OF A LARGE ADMINISTRATIVE DATABASE
Nordyke RJ1, Shaw M2, Goldberg GA2, Vendiola RM2, Batra D2,
Thomasson JW2, 1Protocare Sciences/UCLA School of Public Health, Santa
Monica, CA, USA; 2Protocare Sciences, Herndon, VA, USA |
| PCV40 |
COST-EFFECTIVENESS OF RAMIPRIL IN PREVENTING CARDIOVASCULAR EVENTS IN
HIGH-RISK PATIENTS
Ganguly R, Parasuraman TV, Wyeth Research, St. Davids, PA, USA |
| PCV41 |
HOSPITAL COSTS AND CHARGES ATTRIBUTABLE TO THE DEVELOPMENT OF ARI/ARF
AFTER CABG
Durtschi AJ1, Pathak DS1, Dasta JF1, Kim S2, Kane SL3, Hoffmann
S1, Kellum JA3, 1The Ohio State University, Columbus, OH, USA; 2Ohio
University, Athens, OH, USA; 3University of Pittsburgh, Pittsburgh,
PA, USA |
| PCV42 |
COST
EFFECTIVENESS STUDY OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR VS.
CONVENTIONAL TREATMENT IN PREVENTING SUDDEN DEATH AMONG PATIENTS WITH
HEART FAILURE
Chen L, Hay JW, University of Southern California, Los Angeles,
CA, USA |
| PCV43 |
PREDICTING THE BURDEN OF CONGESTIVE HEART FAILURE (CHF) IN A MANAGED
CARE SETTING: A NEW MODEL TO
PREDICT OUTCOMES AND EVALUATE THE COST-BENEFIT OF CHF MANAGEMENT
Joglekar A, Chao C, Kadison P, Medical Scientists, Inc,
Boston, MA, USA |
| PCV44 |
EVALUATION ON THE COST OF MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN
A LOCAL PUBLIC HOSPITAL IN HONG KONG
Lee VW1, Chan WK2, Lam NL1, Lee KK1, 1The Chinese University of
Hong Kong, Hong Kong, China; 2Division of Cardiology, United Christian
Hospital, Kwun Tong, Hong Kong |
| PCV45 |
HOSPITALIZATION EXPENDITURE OF ACUTE RHEUMATIC FEVER AND CHRONIC
RHEUMATIC HEART DISEASE IN THE UNITED STATES
Liu Z1, Paramore C2, Ciesla G2, Shulman S3, Ciuryla V1, 1Wyeth
Research, Philadelphia, PA, USA; 2MEDTAP International, Bethesda, MD,
USA; 3Northwestern University, Evanston, IL, USA |
| PCV46 |
NEW
SOFTWARE TO ESTIMATE COSTS AND CALCULATE THE RETURN ON INVESTMENT OF
TOBACCO CONTROL PROGRAMS IN A MANAGED CARE SETTING: MEDISAVE SMOKING
CESSATION
Chao C1, Joglekar A1, Foldes SS2, Manley M2, Alesci N2,
Kadison P1, 1Medical Scientists, Inc, Boston, MA, USA; 2Blue Cross
Blue Shield of Minnesota, Eagan, MN, USA |
| PCV47 |
PREDICTING THE SAVINGS AND RETURN ON INVESTMENT OF TOBACCO CONTROL
PROGRAMS IN A MANAGED CARE SETTING USING MEDISAVE SMOKING CESSATION
Chao C1, Joglekar A1, Foldes SS2, Manley M2, Alesci N2,
Kadison P1, 1Medical Scientists, Inc, Boston, MA, USA; 2Blue Cross
Blue Shield of Minnesota, Eagan, MN, USA |
| |
Quality of Life
Presentations |
|
|
| PCV48 |
COMPARISON OF WEIGHT-RELATED QUALITY OF LIFE IMPACTS BY AGE AND GENDER
Martin ML1, Bushnell DM1, Patrick DL2, 1Health Research
Associates, Inc (HRA), Seattle, WA, USA; 2University of Washington,
Seattle, WA, USA |
| PCV49 |
COMPARISON OF WEIGHT-RELATED SYMPTOMS AND QUALITY-OF-LIFE IMPACTS BY
BODY MASS INDEX
Bushnell DM1, Martin ML1, Patrick DL2, 1Health Research
Associates, Inc (HRA), Seattle, WA, USA; 2University of Washington,
Seattle, WA, USA |
| PCV50 |
DESCRIPTION AND PREDICTIVE MODELING OF PERCEIVED
WORK PERFORMANCE IN AN ACUTE CORONARY SYNDROME POPULATION
Ellis JJ, Erickson SR, Kline-Rogers EM, Smith DE, Cooper JV,
Eagle KA, University of Michigan, Ann Arbor, MI, USA |
| PCV51 |
PREDICTIVE MODELS OF HEALTH-RELATED QUALITY OF LIFE
UTILIZING PATIENT REPORTED OUTCOMES DATA FROM A POPULATION WITH A
HISTORY OF ACUTE CORONARY SYNDROME
Ellis JJ, Erickson SR, Kline-Rogers EM, Smith DE, Cooper JV,
Eagle KA, University of Michigan, Ann Arbor, MI, USA |
| PCV52 |
WHICH STATIN? A MULTICRITERIA DECISION ANALYSIS
Dolan JG, Unity Health System/University of Rochester,
Rochester, NY, USA |
|
DIABETES |
| |
Clinical Outcomes/Healthcare Policy Presentations |
|
|
| PDB1 |
RELATION BETWEEN MEDICATION COMPLIANCE AND GLUCOSE CONTROL IN PATIENTS
WITH TYPE 2 DIABETES
Shi SG1, Knight T1, Livengood KB2, Lubowski T2, Walden S2, Nichol
MB1, 1University of Southern California, Los Angeles, CA, USA;
2Pfizer, Inc, New York, NY, USA |
| PDB2 |
IMPROVEMENT OF HEMOGLOBIN A1C (HBA1C) TESTING AND ANALYSIS OF
PARTICIPANT- REPORTED RESULTS IN CAREPATTERNS® FOR DIABETES PROGRAM
Slezak J, Hu L, Berger J, Caremark, Northbrook, IL, USA |
| PDB3 |
EFFICACY OF INSULIN GLARGINE IN PATIENTS WITH TYPE 1 AND 2 DIABETES
Plauschinat CA, Cryar AK, Godley PJ, Nguyen AB, Browne BA,
Scott & White Memorial Hospital, Temple, TX, USA |
| PDB4 |
OBTAINING QUALITY REAL-WORLD TREATMENT DATA FOR ECONOMIC MODELS:
METHODOLOGY AND RESULTS OF A WOUND CARE MEDICAL RECORD ABSTRACTION
STUDY
Hazard EH, Klingman CD, Semroc GN, ValueMedics Research, LLC,
Alexandria, VA, USA |
| PDB5 |
MEDICATION COMPLIANCE IN TYPE 2 DIABETES SUBJECTS: RETROSPECTIVE DATA
ANALYSIS
Rajagopalan R1, Joyce A2, Ollendorf D2, Murray FT1, 1Takeda
Pharmaceuticals North America, Inc, Lincolnshire, IL, USA;
2PharMetrics Inc, Watertown, MA, USA |
| PDB6 |
FACTORS ASSOCIATED WITH HIGH-RISK DIABETIC PATIENTS IN THE CALIFORNIA
MEDICAID POPULATIONS (MEDI-CAL)
Chaikledkaew U1, Wu E2, Johnson KA1, 1University of Southern
California, Los Angeles, CA, USA; 2Analysis Group/Economics, Boston,
MA, USA |
| PDB7 |
DIABETES RELATED DRUG UTILIZATION AND EXPENDITURES IN MEDICARE
BENEFICIARIES WITH AND WITHOUT SUPPLESUPPLEMENTAL PRESCRIPTION DRUG
INSURANCE
D'Souza AO, Madhavan S, West Virginia University, Morgantown,
WV, USA |
| PDB8 |
WITHDRAWN |
| PDB9 |
IMPACT OF AGE, GENDER, AND OUT-OF-POCKET COSTS ON THE TIME TO
DISCONTINUATION OF ORAL ANTI-DIABETIC AGENTS AMONG PATIENTS WITH TYPE
2 DIABETES
Raut M, Gause D, Law AW, Sung J, Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA |
| PDB10 |
A
METHODOLOGY TO IDENTIFY HIGH-RISK PATIENTS WITH DIABETES IN THE
CALIFORNIA MEDICAID POPULATION (MEDI-CAL)
Chaikledkaew U1, Wu E2, Johnson KA1, 1University of Southern
California, Los Angeles, CA, USA; 2Analysis Group/Economics, Boston,
MA, USA |
| PDB11 |
DETERMINATION OF ASSOCIATION BETWEEN DRUG COSTS AND MEDICAL COSTS IN
PATIENTS WITH TYPE 1 DIABETES
Shah S1, Siganga W2, Huang B2, Holiday-Goodman M2, 1University
of Texas at Austin, Austin, TX, USA; 2The University of Toledo,
Toledo, OH, USA |
| |
Economic Outcomes Presentations |
|
|
| PDB12 |
A
COMPARISON OF TWO METHODS FOR ESTIMATING HEALTH CARE COSTS OF DIABETES
Gause D1, Law AW2, Singhal PK3, 1Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA; 2Duke Clinical Research Institute,
Durham, NC, USA; 3University of Maryland, Baltimore, MD, USA |
| PDB13 |
USING LINEAR REGRESSION TO APPROXIMATE RESULTS OF DECISION ANALYSIS:
AN APPLICATION TO A COST COMPARISON ACROSS THREE FIRST-LINE DRUG
STRATEGIES IN TYPE 2 DIABETES
Botteman M, Gao X, Stephens J, Abt Associates Clinical Trials,
Bethesda, MD, USA |
| PDB14 |
RESOURCE UTILIZATION USING INNOLET VS. VIAL/SYRINGE FOR DAILY INSULIN
INJECTION IN A SUBGROUP OF ELDERLY DIABETIC PATIENTS
Nicklasson L1, Lyness W1, Liang J1, Skovlund S2, Lytzen L2,
1Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA; 2Novo Nordisk
A/S, Bagsvaerd, Denmark |
| PDB15 |
COST-EFFECTIVENESS ANALYSIS OF GRAFTSKIN (APLIGRAF) AND BECAPLERMIN (REGRANEX)
IN DIABETIC NEUROPATHIC FOOT ULCERS
Park J, Hay J, University of Southern California, Los Angeles,
CA, USA |
| PDB16 |
COST
OF TYPE 2 DIABETES CARE IN AUSTRALIA – THE DIABCOST STUDY
Colagiuri S1, Conway B2, Grainger D3, Davey P4, Colagiuri R5,
Graham-Clarke P6, FitzGerald P4, Le Reun C4, Price N4, 1Prince of
Wales Hospital, Sydney, NSW, Australia; 2Diabetes Australia Ltd,
Canberra, ACT, Australia; 3Eli Lilly Australia Pty Ltd, Sydney, NSW,
Australia; 4Medical Technology Assessment Group, Chatswood West, NSW,
Australia; 5Australian Centre for Diabetes Strategies, Sydney, NSW,
Australia; 6Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia |
| PDB17 |
ECONOMIC ANALYSIS OF THE USE OF ANGIOTENSIN CONVERTING ENZYME
INHIBITORS IN PATIENTS WITH DIABETES MELLITUS
Zammit DC, Hay JW, University of Southern California, Los
Angeles, CA, USA |
| PDB18 |
ESTIMATING THE COST-EFFECTIVENESS OF REPAGLINIDE PLUS METFORMIN VS.
NATEGLINIDE PLUS METFORMIN OVER A 30-YEAR PERIOD
Nicklasson L1, Palmer A2, Gall MA3, Roze S2, 1Novo Nordisk
Pharmaceuticals, Princeton, NJ, USA; 2CORE Center for Outcomes
Research, Basel, Switzerland; 3Novo Nordisk A/S, Bagsvaerd, Denmark
|
| PDB19 |
THE
COST-EFFECTIVENESS OF TARKA FOR PREVENTING RENAL FAILURE IN TYPE 2
DIABETIC PATIENTS WITH HYPERTENSION IN THE US HEALTHCARE SETTING
Nuijten M1, Wittenberg W2, Kosa J1, 1MEDTAP International, Jisp,
Netherlands; 2Abbott GmbH & Co. KG, Ludwigshafen, Germany |
| PDB20 |
SIMULATING THE LONG TERM COST-EFFECTIVENESS OF A COMBINATION REGIMEN
OF REPAGLINIDE PLUS ROSIGLITAZONE VS. ROSIGLITAZONE MONOTHERAPY OVER A
30-YEAR PERIOD
Nicklasson L1, Palmer A2, Roze S2, 1Novo Nordisk
Pharmaceuticals Inc, Princeton, NJ, USA; 2CORE Center for Outcomes
Research, Basel, Switzerland |
| PDB21 |
COMPARISON OF HEALTHCARE COSTS FOR REPAGLINIDE,
METFORMIN, REPAGLINIDE/METFORMIN, AND GLYBURIDE/
METFORMIN WITHIN A MANAGED CARE ORGANIZATION
Stockl K1, Vanderplas A1, Nicklasson L2, 1Prescription
Solutions, Costa Mesa, CA, USA; 2Novo Nordisk Pharmaceuticals,
Princeton, NJ, USA |
| PDB22 |
THE
DIRECT COST OF DIABETES TYPE 2 IN POLAND –
PRELIMINARY DATA FROM CODIP STUDY
Kinalska IT1, Niewada MP2, Glogowski CA3, Krzyzanowska AM3,
Pietrasik A2, _atek M4, Kamiñski B4, Gierczynski JM3, Tomaszewski WW3,
1Medical University of Bialystok, Poland, Bialystok, Poland; 2Medical
University of Warsaw, Warsaw, Poland; 3GlaxoSmithKline Pharmaceuticals
S.A, Warsaw, Poland; 4Warsaw School of Economics, Warsaw, Poland
|
| PDB23 |
INVESTIGATOR AND SITE CHARACTERISTICS OF THE NAVIGATOR TRIAL
Friedman JY1, Curtis L1, Gnanasakthy A2, Whellan D1, Schulman
KA1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis
Pharmaceuticals, East Hanover, NJ, USA |
| PDB24 |
FACTORS INFLUENCING THE DIAGNOSTIC TESTS PRESCRIBING FOR TYPE 2
DIABETES IN AMBULATORY PATIENTS
Rahman AM, St. John's University, Jamaica, NY, USA |
| PDB25 |
COST
ANALYSIS OF DIABETES TREATMENT WITH GLARGINE INSULIN OR NPH INSULIN IN
SPAIN
Rubio-Terrés C1, Rodriguez J1, Bolinder B2, 1Aventis Pharma,
S.A, Madrid, Spain; 2Aventis Pharmaceuticals, Bridgewater, NJ, USA
|
| |
Quality
of Life Presentations |
|
|
| PDB26 |
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH NEUROPATHY USING THE
NORFOLK QUALITY OF LIFE (QOL) TOOL
Vinik EJ, Stansberry KB, Ruck SM, Vinik AI, EVMS, Norfolk, VA,
USA |
| PDB27 |
RISKING HEALTH TO AVOIDING INJECTIONS – STATED PREFERENCES OF TYPE 2
DIABETICS IN THE US AND CANADA
Hauber AB1, Johnson FR2, 1RTI Health Solutions, Hatboro, PA,
USA; 2Research Triangle Institute, Research Triangle Park, NC, USA |
| PDB28 |
DEVELOPMENT OF AN INSTRUMENT TO MEASURE PATIENT EXPECTATION AND
PREFERENCE FOR THE INSULIN INJECTION PEN
Szeinbach SL1, Summers KH2, Lenox SM2, 1Ohio State University,
Columbus, OH, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
|
|
HEMATOLOGIC/PITUITARY DISORDERS |
| |
Economic Outcomes Presentations |
|
|
| PPT1 |
COST-EFFECTIVENESS OF RECOMBINANT HUMAN ERYTHROPOIETIN FOR PREVENTING
TRANSFUSIONS IN CRITICALLY ILL PATIENTS
Sullivan PW, MacLaren R, University of Colorado School of
Pharmacy, Denver, CO, USA |
| PPT2 |
COST
ANALYSIS OF PROPHYLACTIC TREATMENT OF CHILDREN WITH SEVERE HEMOPHILIA
A IN CANADA
Zwaan T1, Heemstra H1, Kern M2, Feldman B2, Blanchette V2,
Hemels MEH3, Einarson T3, 1Utrecht University, Utrecht, Netherlands;
2Hospital for Sick Children, Toronto, ON, Canada; 3University of
Toronto, Toronto, ON, Canada |
| PPT3 |
COST-EFFECTIVENESS OF TRANSFUSING PLATELET COMPONENTS PREPARED WITH
PATHOGEN INACTIVATION TREATMENT IN ORTHOPEDIC SURGERY IN THE UNITED
STATES
Gao X1, Botteman MF1, Weissfeld JL2, Pashos C3, Triulzi D4,
Staginnus U5, 1Abt Associates Clinical Trials, Bethesda, MD, USA;
2University of Pittsburgh, Pittsburgh, PA, USA; 3Abt Associates
Clinical Trials, Cambridge, MA, USA; 4The Institute for Transfusion
Medicine, Pittsburgh, PA, USA; 5Baxter, S.L, Madrid, Spain |
| PPT4 |
THE
ECONOMIC IMPACT OF NOVOSEVEN® IN STEM CELL TRANSPLANTATION IN GERMANY
AND THE UNITED STATES
Hart WM1, Dangata Y2, 1EcoStat Consulting Group, Madrid, Spain;
2EcoStat Consulting UK, Northrepps, Norfolk, UK |
| PPT5 |
LONG
TERM COST OF ILLNESS STUDY FOR SEVERE HEMOPHILIC CHILDREN IN TORONTO
Heemstra H1, Zwaan T1, Kern M2, Feldman B2, Blanchette V2,
Hemels MEH3, Einarson T3, 1Utrecht University, Utrecht, Netherlands;
2Hospital for Sick Children, Toronto, ON, Canada; 3University of
Toronto, Toronto, ON, Canada |
| PPT6 |
HEMOPHILIA ECONOMIC MODEL OF OUTCOMES: CASE STUDY
Evans C1, Roberts HR2, Sagrolikar A3, Gomperts E3, Poulios N3,
1Mapi Values, Boston, MA, USA; 2University of North Carolina, Chapel
Hill, NC, USA; 3Baxter Healthcare Corporation, Westlake Village, CA,
USA |
| |
Quality
of Life Presentations |
|
|
| PPT7 |
IMPROVEMENT IN QUALITY OF LIFE AND HEALTHCARE UTILISATION DURING
GROWTH HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE
NETHERLANDS
den Hartog M1, van Kuijck MA1, Koppeschaar HPF2, Mattsson AF3,
Koltowska-Häggström M3, 1Pharmacia BV, Woerden, Netherlands; 2Utrecht
Medical Centre, Utrecht, Netherlands; 3Pharmacia AB, Stockholm, Sweden
|
| PPT8 |
DEVELOPMENT OF THE GROWTH HORMONE INJECTION QUESTIONNAIRE (GHIQ) FOR
ADOLESCENTS
Cramer JA1, Simeoni MC2, Auquier P2, Brasseur P3, Beresniak A3,
1Yale University School of Medicine, West Haven, CT, USA; 2University
of Medicine, Marseille, France; 3Serono International SA, Geneva,
Switzerland |
| PPT9 |
HEALTHCARE CONSUMPTION, QOL, AND PATIENT-REPORTED OUTCOMES DURING GH
REPLACEMENT IN HYPOPITUITARY ADULTS: RESULTS FROM THE GERMAN KIMS
COHORT
Kann P1, Buchfelder M2, Mattsson A3, Koltowska Häggström M3,
Metzeler H4, Saller B4, 1University of Marburg, Marburg, Germany;
2University of Goettingen, Goettingen, Germany; 3Pharmacia AB,
Stockholm, Sweden; 4Pharmacia GmbH, Erlangen, Germany |
|
MENTAL HEALTH |
| |
Clinical Outcomes/Healthcare Policy Presentations |
|
|
| PMH1 |
QUALITY ASSESSMENT OF META-ANALYSES OF RCTS OF PHARMACOTHERAPY IN
MAJOR DEPRESSIVE DISORDER
Hemels MEH, Vicente C, Sadri H, Masson MJ, Einarson T,
University of Toronto, Toronto, ON, Canada |
| PMH2 |
A
META-ANALYSIS AND COMMON COMPARATOR ANALYSIS OF OLANZAPINE VERSUS
ZIPRASIDONE AND ARIPIPRAZOLE
Davey PJ1, Mudge MAC1, Croker VS2, Aldridge G1, FitzGerald P1,
1Medical Technology Assessment Group, Chatswood West, NSW, Australia;
2Eli Lilly Australia Pty Ltd, West Ryde, Australia |
| PMH3 |
THE
TREATMENT CHARACTERISTICS AND OUTCOMES OF PERSONS WITH DEPRESSION AND
ALCOHOLISM
Mark TL, The MEDSTAT Group, Inc, Washington, DC, USA |
| PMH4 |
ANALYSIS OF HEALTHCARE UTILIZATION PATTERNS AND ADHERENCE IN PATIENTS
RECEIVING ANTIPSYCHOTIC
MEDICATIONS
Al-Zakwani IS1, Barron JJ1, Bullano MF1, Arcona S2, Drury CJ1,
Cockerham T3, 1Health Core, Inc, Newark, DE, USA; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA; 3WellPoint
Pharmacy Management, West Hills, CA, USA |
| PMH5 |
THE
IMPACT OF MIRTAZAPINE COMPARED TO NON-TCA ANTIDEPRESSANTS ON WEIGHT
CHANGE IN NURSING FACILITY RESIDENTS
Tonnu IQ1, McCombs JS2, Williams BR1, Yu AP1, 1USC School of
Pharmacy, Los Angeles, CA, USA; 2University of Southern California,
Los Angeles, CA, USA |
| PMH6 |
EVALUATING THE EFFECTIVENESS OF FLUOXETINE 90MG ADMINISTERED EVERY
WEEK AND EVERY 2 WEEKS IN NURSING HOME RESIDENTS
Bellnier T, Karki S, Ortega T, Decatur A, School of Pharmacy,
SUNY at Buffalo, Rochester, NY, USA |
| PMH7 |
A
MARKOV COHORT SIMULATION ESTIMATING THE RISK OF DEVELOPING CORONARY
HEART DISEASE IN PATIENTS USING ANTIPSYCHOTIC DRUGS
Tahami Monfared AA1, Gueylard Chenevier D1, Lescrauwaet
B2, LeLorier J1, 1Centre Hospitalier de l'Université de Montréal,
Campus Hôtel Dieu, Montreal, QC, Canada; 2Pfizer Canada Inc, Kirkland,
QC, Canada |
| PMH8 |
PHARMACOLOGIC TREATMENT OF HOSPITALIZED PATIENTS WITH BIPOLAR DISORDER
Gaylord B1, Zhao Z2, Wang PF1, Gutierrez B1, 1Premier, Inc,
Charlotte, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
|
| PMH9 |
INFLUENCE OF PHYSICIAN MIX AND SUPPLY ON THE DIFFUSION OF ATYPICAL
ANTIPSYCHOTIC AGENTS
Shetty SS, Brooks JM, University of Iowa, Iowa City, IA, USA
|
| PMH10 |
ETHNICITY AND SCHIZOPHRENIA MEDICATION CHOICE:
HALOPERIDOL, RISPERIDONE, OR OLANZAPINE
Opolka JL1, Rascati KL2, Brown CM2, Gibson PJ1, 1Eli Lilly and
Company, Indianapolis, IN, USA; 2University of Texas at Austin,
Austin, TX, USA |
| PMH11 |
DOES
THE SHORT-TERM ADMINISTRATION OF A BENZODIAZEPINE IMPROVE COMPLIANCE
WITH ANTIDEPRESSANT THERAPY?
Mark TL1, Kevin M2, Torigoe Y2, 1Medstat, Washington, DC, USA;
2Pharmacia Corporation, Peapack, NJ, USA |
| PMH12 |
ASSESSING THE RELATIONSHIP OF GENERALIZED ANXIETY DISORDER AND PEPTIC
ULCER DISEASE
Kassulke JP, Marks AS, Patel H, Caremark, Inc, Northbrook, IL,
USA |
| PMH13 |
POLYPHARMACOTHERAPY OF INPATIENTS WITH SCHIZOPHRENIA
Zhao Z1, Wang PF2, Gutierrez B2, Gaylord B2, 1Eli Lilly and
Company, Indianapolis, IN, USA; 2Premier, Inc, Charlotte, NC, USA
|
| PMH14 |
CLINICAL PROFILES OF SSRI USERS: FACTS EXTRACTED FROM HEALTHCARE
CLAIMS DATA
Huang X, Lynn TE, Lutgen J, Ingenix, Eden Prairie, MN, USA
|
| PMH15 |
PREDICTORS OF DURATION OF VISITS AMONG PATIENTS DIAGNOSED WITH
DEPRESSION IN THE AMBULATORY MEDICAL CARE SETTINGS
Hou X, University of California, Berkeley, Berkeley, CA, USA
|
| PMH16 |
PREVALENCE AND TRENDS IN ANTIPSYCHOTIC POLYPHAR
MACY AMONG MEDICAID ELIGIBLE SCHIZOPHRENIA PATIENTS IN CALIFORNIA AND
GEORGIA, 1998-2000
Ganguly R, Miller LS, Martin BC, University of Georgia, Athens,
GA, USA |
| PMH17 |
USE
OF SEDATIVE/HYPNOTIC AGENTS BY AN ELDERLY AMBULATORY POPULATION
Carlson AM1, Morris LS2, 1Data Intelligence Consultants LLC,
Eden Prairie, MN, USA; 2IMS Health, Plymouth Meeting, PA, USA |
| PMH18 |
RETROSPECTIVE DRUG USE EVALUATION OF ANTIPSYCHOTIC AGENTS IN THE
VETERANS ADMINISTRATION SYSTEM: A POPULATION BASED APPROACH
Shermock KM1, Secic M2, Fuller MA3, Dodd S4, 1Shermock Health
Outcomes Research, Columbia, MD, USA; 2Secic Statistical Consulting,
Cleveland, OH, USA; 3Louis Stokes Department of Veterans Affairs
Medical Center, Brecksville, OH, USA; 4Janssen Pharmaceutica,
Titusville, NJ, USA |
| PMH19 |
DIFFERENCES AMONG ANTIPSYCHOTICS IN THE TIME TO ALL-CAUSE DRUG
DISCONTINUATION: RESULTS FROM A LONGITUDINAL NATURALISTIC STUDY OF
SCHIZOPHRENIA
Zhu B1, Ascher-Svanum H1, Faries D1, Gibson J1, Ernst F1,
Swartz M2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Duke
University Medical Center, Durham, NC, USA |
| PMH20 |
IMPACT OF A CONVERSION PROGRAM FROM SERTRALINE TO GENERIC FLUOXETINE
IN A STAFF-MODEL MANAGED CARE ORGANIZATION ENHANCED BY PHYSICIAN
PROFILING AND ACADEMIC DETAILING
Plauschinat CA, Godley PJ, Woodward BW, Clanton CW, Jackimiec
JM, Chaddick J, Browne BA, Scott & White Memorial Hospital, Temple,
TX, USA |
| PMH21 |
REINFORCE AND ADVOCATE COMMUNITY AND SCHOOL EDUCATIONAL PROGRAM IN
SAFETY USE OF MEDICATION AND PREVENTION OF DRUG ABUSE IN CENTRAL OF
TAIWAN
Lin HW, Lai CJ, Lin CC, Tsai HY, China Medical College
Hospital, Taichung, Taiwan |
| |
Economic Outcomes Presentations |
|
|
| PMH22 |
A
NATIONAL ESTIMATE OF INDIRECT COSTS ASSOCIATED WITH ANXIETY DISORDERS
Mychaskiw MA, Sankaranarayanan J, Purdue University, West
Lafayette, IN, USA |
| PMH23 |
PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT
OF ANXIETY DISORDERS: HOMEOPATHY AND PSYCHOTROPICS
Trichard M1, Chaufferin G1, Nicoloyannis N2, 1Laboratoires
Boiron, Sainte-Foy-Lès-Lyon, France; 2Université Lumière Lyon 2, Bron,
France |
| PMH24 |
COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS PLACEBO IN RELAPSE
PREVENTION IN PATIENTS WITH SOCIAL ANXIETY
DISORDER
Servant D1, Montgomery SA2, François C3, Despiegel N3, 1CHU
Lille, Lille, France; 2Imperial College, London, UK; 3Lundbeck SA,
Paris, France |
| PMH25 |
SOCIAL ANXIETY DISORDER: EFFECT OF RELAPSE ON COSTS AND QUALITY OF
LIFE
Montgomery SA1, Servant D2, Rachidi S3, François C3, 1Imperial
College, London, UK; 2CHU Lille, Lille, France; 3Lundbeck SA, Paris,
France |
| PMH26 |
COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR MANIA
McGarry LJ1, Bird A2, Thompson D1, Wang P3, Martin SC4,
Weinstein MC2, 1Innovus Research, Inc, Medford, MA, USA;
2Harvard School of Public Health & Innovus Research, Inc, Boston, MA,
USA; 3Brigham & Women's Hospital, Boston, MA, USA; 4Johnson & Johnson
Pharmaceutical Services, L.L.C, Raritan, NJ, USA |
| PMH27 |
EFFECTS OF PATIENTS WITH BIPOLAR, SCHIZOPHRENIC, AND MAJOR DEPRESSIVE
DISORDERS ON THE MENTAL AND OTHER HEALTHCARE EXPENSES OF FAMILY
MEMBERS
Gianfrancesco F1, Yu E2, White R2, Wang RH1, 1HECON Associates,
Inc, Montgomery Village, MD, USA; 2AstraZeneca Pharmaceuticals,
Wilmington, DE, USA |
| PMH28 |
THE
IMPACT OF UNRECOGNIZED BIPOLAR DISORDERS FOR PATIENTS TREATED WITH
ANTIDEPRESSANT MEDICATIONS
Thiebaud P1, McCombs JS1, Shi L2, 1University of Southern California,
Los Angeles, CA, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
|
| PMH29 |
ECONOMIC BURDEN OF NOT
RECOGNIZING BIPOLAR DISORDER PATIENTS
Birnbaum HG1, Dial E1, Oster EF1, Greenberg PE1, Shi L2,
1Analysis Group/Economics, Boston, MA, USA; 2Eli Lilly and Company,
|
| PMH30 |
A
COMPARISON OF MENTAL HEALTH RESOURCES USED BY PATIENTS WITH BIPOLAR
DISORDER TREATED WITH RISPERIDONE, OLANZAPINE, OR QUETIAPINE
Gianfrancesco FD1, Wang RH2, White RE2, Yu E2, 1HECON
Associates, Inc, Montgomery Village, MD, USA; 2Astrazeneca
Pharmaceuticals, Wilmington, DE, USA |
| PMH31 |
PATTERNS OF TREATMENT AMONG BIPOLAR DISORDER PATIENTS TREATED WITH
ANTIDEPRESSANTS
Birnbaum HG1, Dial E1, Oster EF1, Greenberg PE1, Shi L2,
1Analysis Group/Economics, Boston, MA, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA |
| PMH32 |
AN
ECONOMIC COMPARISON OF ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA
Sorensen SV1, Russell JM2, Mackell JA3, 1MEDTAP International,
Bethesda, MD, USA; 2University of Texas Medical Branch, Galveston, TX,
USA; 3Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA
|
| PMH33 |
OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA: A
MENTAL HEALTH COST COMPARISON IN A MANAGED CARE SETTING
Sommers S1, Lynch F2, McFarland B3, Muilenburg N2, 1Group
Health Cooperative, Seattle, WA, USA; 2Kaiser Permanente Northwest,
Portland, OR, USA; 3Oregon Health & Science University, Portland, OR,
USA |
| PMH34 |
COMPARISON OF OLANZAPINE VERSUS QUETIAPINE IN THE TREATMENT OF
HOSPITALIZED PATIENTS WITH SCHIZOPHRENIA
Wang PF1, Zhao Z2, 1Premier, Inc, Charlotte, NC, USA; 2Eli
Lilly and Company, Indianapolis, IN, USA |
| PMH35 |
ATYPICAL ANTIPSYCHOTICS: TREATMENT PATTERNS, UTILIZATION AND COST
AMONG MANAGED CARE ENROLLEES
Hall JA1, Dodd SL2, Nelson MA1, 1Ingenix Pharmaceutical
Services, Eden Prairie, MN, USA; 2Janssen Pharmaceutica, Titusville,
NJ, USA |
| PMH36 |
ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTICS WITHIN THE WISCONSIN
MEDICAID PROGRAM
Sanchez RJ1, Conner C2, 1Univeristy of Texas, Ausitn, TX, USA;
2Pfizer, Inc, Milwaukee, WI, USA |
| PMH37 |
THE
ECONOMIC BURDEN OF DEPRESSION IN 2000
Greenberg P1, Kessler R2, Corey-Lisle P3, Birnbaum H1, Leong
S1, Lowe S1, 1Analysis Group/Economics, Boston, MA, USA; 2Harvard
University, Boston, MA, USA; 3Eli Lilly and Company, Indianapolis, IN,
USA |
| PMH38 |
A
STUDY OF THE ECONOMIC BURDEN OF DEPRESSION
Trivedi DN, Bollu V, Lawrence L, The University of Louisiana at
Monroe, Monroe, LA, USA |
| PMH39 |
DEPRESSION AND FIBROMYALGIA: TREATMENT AND COST WHEN DIAGNOSED
SEPARATELY OR CONCURRENTLY
Robinson R1, Birnbaum HG2, Sisitsky T2, Greenberg P2, Wolfe F3,
1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group/
Economics, Boston, MA, USA; 3National Databank for Rheumatic Diseases,
Wichita, KS, USA |
| PMH40 |
EVALUATING THE COST-EFFECTIVENESS OF ST. JOHN'S WORT VERSUS FLUOXETINE
FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION
Thayer LA1, Scott V1, Nau D2, Rosenbluth S1, Makela G1, 1West
Virginia University, Morgantown, WV, USA; 2University of Michigan, Ann
Arbor, MI, USA |
| PMH41 |
IMPACT OF DEPENDENTS’ DEPRESSION ON EMPLOYEE HEALTH BENEFITS COST:
QUANTIFYING THE BURDEN OF CARE
Kleinman N, Muchmore L, Gardner H, Options & Choices,
Inc, Cheyenne, WY, USA |
| PMH42 |
TREATMENT OF DEPRESSION: ESCITALOPRAM HAS SIMILAR EFFICACY BUT LOWER
COSTS COMPARED TO VENLAFAXINE XR
Montgomery SA1, Fernandez JL2, François C3, 1Imperial College,
London, UK; 2London School of Economics, London, UK; 3Lundbeck SA,
Paris, France |
| PMH43 |
THE
COST-UTILITY OF BUPROPION SR VERSUS SERTRALINE IN THE TREATMENT OF
LATE-LIFE DEPRESSION
Suter KL, Biddle A, University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA |
| PMH44 |
UTILIZATION AND COST OF ATYPICAL ANTIPSYCHOTICS IN MEDICAID PATIENTS
WITH DEPRESSION
Markowitz J1, Meletiche DM2, 1Health Data Analytics, Princeton
Junction, NJ, USA; 2Janssen Pharmaceutica, Inc, Titusville, NJ, USA
|
| PMH45 |
COSTS AND EFFECTIVENESS OF METHADONE AND BUPRENORPHINE MAINTENANCE
TREATMENTS IN WESTERN AUSTRALIA
Cheng YY, Sunderland VB, Shaw T, Curtin University of
Technology, Perth, WA, Australia |
| PMH46 |
COST
CONSEQUENCES OF APPLYING APPROPRIATE USE EDITS TO SELECT HYPNOTIC
AGENTS: A RETROSPECTIVE COMPARATIVE ANALYSIS
Chiefari DM, NMHCrx, Latham, NY, USA |
| |
Quality
of Life Presentations |
|
|
| PMH47 |
VALIDATION OF ENGLISH AND CHINESE VERSIONS OF THE
SQLS, SF-36 AND HUI3 IN PATIENTS WITH SCHIZOPHRENIA IN SINGAPORE
Luo N1, Seng BK2, Thumboo J1, Li SC1, 1National University of
Singapore, Singapore, Republic of Singapore; 2Institute of Mental
Health, Singapore, Republic of Singapore |
| PMH48 |
SUBJECTIVE TOLERABILITY WITH ZIPRASIDONE VS HALOPERIDOL IN ACUTE
SCHIZOPHRENIA
Awad AG1, Voruganti LN2, Mackell JA3, Siu CO3, 1Institute of
Medical Science, University of Toronto, Toronto, ON, Canada;
2University of Western Ontario, London, ON, Canada; 3Pfizer
Pharmaceuticals Group, Pfizer Inc, New York, NY, USA |
| PMH49 |
PERFORMANCE OF THE SF-12 AND RAND-12 PHYSICAL AND MENTAL HEALTH
SUMMARY SCORES IN PEOPLE PRACTICING MEDITATION
Treesak C, Ye X, Sakthong P, Gross C, University of Minnesota,
Minneapolis, MN, USA |
| PMH50 |
COMORBID DIABETES AND SCHIZOPHRENIA: IMPACT ON HEALTHCARE RESOURCE USE
Mackell JA, Warrington LE, Loebel A, Pfizer Inc, New York, NY,
USA |
| PMH51 |
IMPACT
OF COMORBID DIABETES ON FUNCTIONING IN SCHIZOPHRENIA
Mackell JA, Warrington LE, Loebel A, Pfizer Inc, New York, NY,
USA |
| PMH52 |
PATIENT-VALUED HEALTH STATE UTILITIES FOR BIPOLAR DISORDER:
DIFFERENCES THAT CAN BE MEASURED
Hanlon JT1, Mannix S1, Kleinman L1, Martin S2, Revicki D1,
1MEDTAP International, Inc, Bethesda, MD, USA; 2J&J Pharmaceuticals
Services, L.L.C, Raritan, NJ, USA |
| PMH53 |
IMPACT OF WEIGHT GAIN ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF
BIPOLAR PATIENTS
Bolge SC1, Meletiche DM2, 1Consumer Health Sciences, Princeton,
NJ, USA; 2Janssen Pharmaceutica, Inc, Titusville, NJ, USA |
| PMH54 |
MENTAL HEALTH COMORBIDITY PREVALENCE, PATTERNS, AND IMPACT ON QUALITY
OF LIFE AMONG GULF WAR VETERANS
Forman VL1, Carney CP1, Peloso P1, Woolson RF2, Black DW1,
Doebbeling BN1, 1University of Iowa, Iowa City, IA, USA; 2Medical
University of South Carolina, Charleston, SC, USA |
| PMH55 |
DO
HEALTH EXPERIENCES IN DEPRESSION CHANGE PATIENTS’ VALUES?
Elnitsky CA1, Lenert LA1, Sherbourne C2, 1University of
California, San Diego, San Diego, CA, USA; 2RAND Corporation, Santa
Monica, CA, USA |
| PMH56 |
QUALITY OF LIFE TRAJECTORIES AMONG MASSACHUSETTS ADULTS WITH SUBSTANCE
USE DISORDERS
Smith KW, Zhang A, Larson MJ, New England Research Institutes,
Watertown, MA, USA |
| PMH57 |
PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY: FRENCH
RESULTS
Myon E, Taïeb C, Pierre Fabre SA, Boulogne Billancourt, France
|
| PMH58 |
COLLEGE STUDENTS AND STRESS: WHAT IS THE CONNECTION? A HUMANISTIC
OUTCOMES ASSESSMENT
White A1, Xiao H2, 1Florida A & M University, Tallahassee, FL,
USA; 2Florida A&M University, Tallahassee, FL, USA |
|
RESPIRATORY DISEASES/DISORDERS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PRP1 |
THE
IMPLEMENTATION OF NEW TREATMENT GUIDELINES IN ASTHMA BY HEALTHCARE
PROVIDERS
Mehta R, Cady P, Idaho State University, Pocatello, ID, USA
|
| PRP2 |
DEVELOPMENT OF A PROSPECTIVE, NON-RANDOMIZED PATIENT REGISTRY TO
MEASURE REAL-WORLD CLINICAL, ECONOMIC, AND HUMANISTIC OUTCOMES
Perry BM1, Legorreta AP2, Darin RM1, Pendergraft TB3,
Chernicoff HO1, O'Connor RD4, 1Health Benchmarks, Inc, Woodland Hills,
CA, USA; 2UCLA, Los Angeles, CA, USA; 3GlaxoSmithKline, Research
Triangle Park, NC, USA; 4UCSD, San Diego, CA, USA |
| PRP3 |
CLINICAL EFFECTIVENESS OF BUDESONIDE AND FORMOTEROL IN A SINGLE
INHALER IN PATIENTS WITH ASTHMA - AN AUDIT IN UK GENERAL PRACTICE
Emmas CE1, Beaumont SD2, 1AstraZeneca UK Ltd, Luton,
Bedfordshire, UK; 2AstraZeneca UK, Luton, Bedfordshire, UK |
| PRP4 |
THE
EFFECT OF A LETTER-BASED EDUCATIONAL PROGRAM FOR PRESCRIBERS AND
PHARMACISTS ON ADHERENCE TO NATIONAL ASTHMA GUIDELINES AND HEALTHCARE
UTILIZATION
Coleman CI1, Reddy P2, Laster-Bradley NM3, Dorval S4, White
CM1, 1University of Connecticut, Storrs, CT, USA; 2Abt Associates
Clinical Trials, Cambridge, MA, USA; 3ACS State Healthcare, Atlanta,
GA, USA; 4Department of Social Services, Hartford, CT, USA |
| PRP5 |
COMPLIANCE WITH ASTHMA CONTROLLER MEDICATIONS: AN ANALYSIS OF GAPS IN
CARE AND OPPORTUNITIES FOR COST REDUCTION
Verbrugge RR, Sokol M, McGuigan K, Medco Health Solutions, Inc,
Franklin Lakes, NJ, USA |
| PRP6 |
COMPARISON OF RISK FOR HOSPITAL AND/OR EMERGENCY DEPARTMENT VISITS FOR
MEDICAID PATIENTS WITH COPD
Rascati KL1, Stanford RH2, Borker RD2, 1University of Texas,
Austin, TX, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA
|
| PRP7 |
USE
OF LONG-TERM ASTHMA CONTROLLER MEDICATIONS BEFORE AND AFTER A
HOSPITALIZATION OR EMERGENCY DEPARTMENT VISIT
Atherly A, Williams SG, Redd SC, Centers for Disease Control,
Atlanta, GA, USA |
| |
Economic Outcomes Presentations |
|
|
| PRP8 |
COMPARISON OF THE ECONOMIC IMPACT OF MONTELUKAST AND INHALED
CORTICOSTEROID AGENTS ON ALLERGIC RHINITIS-RELATED UTILIZATION IN
PATIENTS WITH ASTHMA
Etemad LR1, Meyer JW1, Gilmet GP2, Standford RH2, Stephens CH2,
1Ingenix, Eden Prairie, MN, USA; 2GlaxoSmithKline, Research Triangle
Park, NC, USA |
| PRP9 |
THE
NET COST OF ASTHMA TO NORTH CAROLINA (NC) MEDICAID AND IDENTIFICATION
OF FACTORS DRIVING COSTS IN AN ASTHMATIC POPULATION
Panicker S1, Nielsen K2, Martin B1, 1University of Georgia,
Athens, GA, USA; 2Global Health Outcomes, GlaxoSmithKline, Raleigh,
NC, USA |
| PRP10 |
PREDICTING THE BENEFIT OF OPTIMIZING SEVERE ASTHMA MANAGEMENT IN A
MANAGED CARE SETTING: A COST-BENEFIT ANALYSIS COMPARING THE
COMBINATION OF FLUTICASONE PROPIONATE AND SALMETEROL (FPS) AND
ZAFIRLUKAST
Joglekar A, Chao C, Kadison P, Medical Scientists, Inc, Boston,
MA, USA |
| PRP11 |
CHANGES IN ASTHMA-RELATED HEALTHCARE UTILIZATION AND COSTS AFTER THE
ADDITION OF SALMETEROL TO A MEDICAID POPULATION
Shah BM, Dodd MA, Gupchup GV, Kelly HW, The University of New
Mexico, Albuquerque, NM, USA |
| PRP12 |
BONE
MINERAL DENSITY LOSS AFFECTS ESTIMATES OF THE COST-EFFECTIVENESS OF
INHALED STEROIDS IN ASTHMA
Paltiel AD1, Fuhlbrigge AL2, Kitch BT2, Rashti R2, Weiss ST2,
Lee SJ3, Kuntz KM3, 1Yale School of Medicine, New Haven, CT, USA;
2Harvard Medical School, Boston, MA, USA; 3Harvard School of Public
Health, Boston, MA, USA |
| PRP13 |
ASSESSING THE COST IMPLICATIONS OF COMBINED PHARMACOTHERAPY IN THE
LONG TERM MANAGEMENT OF ASTHMA
Wu EQ1, Johnson KA2, Nichol MB2, 1Analysis Group/Economics,
Boston, MA, USA; 2University of Southern California, Los Angeles, CA,
USA |
| PRP14 |
RATES OF ASTHMA-RELATED MEDICAL AND PRESCRIPTION RESOURCE UTILIZATION
AND COSTS IN A MEDICAID POPULATION
Joshi AV1, Smith MJ2, 1West Virginia University/Pfizer Inc,
Morgantown, WV, USA; 2West Virginia University, Morgantown, WV, USA
|
| PRP15 |
RELATIONSHIP BETWEEN ADHERENCE RATE AND TOTAL MEDICAL AND DRUG COSTS
Peterson AM, Ceccanecchio D, McGhan WF, Philadelphia College of
Pharmacy, Philadelphia, PA, USA |
| PRP16 |
RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) AFTER
INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997)
Mehta R1, Cady P2, 1Idaho State University, Salt Lake City, UT,
USA; 2Idaho State University, Pocatello, ID, USA |
| PRP17 |
THE
AVERAGE COSTS OF THE TREATMENT OF ASTHMA EXACERBATIONS IN IN-PATIENT
CARE AND HOSPITAL EMERGENCY ROOM IN POLAND
Plisko R1, Wcislo J1, Landa K1, Glogowski CA2, Gierczynski JM2,
1HTA Consulting, Krakow, Malopolska, Poland; 2GlaxoSmithKline
Pharmaceuticals S.A, Warszawa, Poland |
| PRP18 |
PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT
OF RECURRENT ACUTE RHINOPHARYNGITIS IN 18-MONTH-OLD TO 4-YEAR-OLD
CHILDREN: HOMEOPATHY AND ANTIBIOTICS
Trichard M1, Chaufferin G1, Nicoloyannis N2, 1Laboratoires
BOIRON, Sainte-Foy-Lès-Lyon, France; 2Université Lumière Lyon 2, Bron,
France |
| PRP19 |
ASTHMA HEALTHCARE EXPENDITURE: THE ROLE OF CAPITATION AND MANAGED CARE
Nurmagambetov T, Atherly A, Williams S, Redd S, Centers for
Disease Control and Prevention, Atlanta, GA, USA |
| PRP20 |
IMPROVING PHARMACEUTICAL CARE BY THE PROCUREMENT OF PALIVIZUMAB
THROUGH SPECIALTY DISTRIBUTION
Walker CL, Howell-Smith D, Saba S, Pena A, Humana Inc,
Louisville, KY, USA |
| PRP21 |
THE
ECONOMIC IMPACT OF HOMEOPATHIC MANAGEMENT: THE FRENCH EXAMPLE
Taïeb C, Myon E, Pierre Fabre SA, Boulogne Billancourt, France
|
| PRP22 |
IS
CISATRACURIUM COST EFFECTIVE FOR NEUROMUSCULAR BLOCKADE IN THE ICU? A
MARKOV COMPUTER SIMULATION STUDY
Macario A1, Marx SE2, Chow JL1, 1Stanford University, Stanford,
CA, USA; 2Abbott Laboratories, Lake Forest, IL, USA |
| PRP23 |
ECONOMIC OUTCOMES OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
WITH INHALED CORTICOSTEROIDS AND LONG-ACTING ß-AGONISTS IN A HEALTH
MAINTENANCE ORGANIZATION
Gagnon YM1, Levy AR2, Hurley JS3, Frost FJ3, Spencer MD4, Maple
DW3, Briggs AH5, 1Occam Research & Consulting, Vancouver, BC, Canada;
2University of British Columbia, Vancouver, BC, Canada; 3Lovelace
Respiratory Research Institute, Albuquerque, NM, USA; 4GlaxoSmithKline
Global Health Outcomes, Uxbridge, Middlesex, UK; 5University of
Oxford, Oxford, UK |
| |
Quality
of Life Presentations |
|
|
| PRP24 |
ASSESSMENT OF THE IMPROVEMENTS IN QUALITY OF LIFE POST-LUNG
TRANSPLANT: A COMPARISON OF RECIPIENTS VERSUS CANDIDATES
Matthees BJ1, Lobo FS2, Gross CR2, 1Minnesota State University,
Moorhead, MN, USA; 2University of Minnesota, Minneapolis, MN, USA
|
| PRP25 |
CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE-C
(CAQ-C) IN SINGAPORE
Chong LY1, Chay OM2, Goh A2, Seng YC2, Li SC1, 1National
University of Singapore, Department of Pharmacy, Singapore, Republic
of Singapore; 2KK Women's and Children’s Hospital, Singapore, Republic
of Singapore |
| PRP26 |
REVIEW OF QUALITY OF LIFE INSTRUMENTS IN PEDIATRIC ASTHMA
Yu AP, Nichol MB, Globe D, University of Southern California,
Los Angeles, CA, USA |
|
WOMEN’S & MEN’S HEALTH |
| |
Clinical Outcomes/Healthcare Policy Presentations |
|
|
| PWM1 |
META-ANALYSIS OF THE EFFECTIVENESS OF MAMMOGRAPHY
Zammit DC, Hay JW, University of Southern California, Los
Angeles, CA, USA |
| PWM2 |
A
MULTIDIMENSIONAL ANALYSIS OF DELIVERY-CARE
Panella M, Marchisio S, University of Eastern Piedmont “A.
Avogadro”, Novara, Italy |
| PWM3 |
COMPARISON OF DIRECT-TO-CONSUMER INTERVENTIONS BY A MEDICAID HEALTH
PLAN TO INCREASE FOLIC ACID SUPPLEMENTATION IN WOMEN OF CHILDBEARING
AGE
Yeh C1, Bultemeier N1, Haxby D1, Buckley D2, Carlson M3,
Inglish J3, Labby D3, 1Oregon State University, Corvallis, OR, USA;
2Oregon Health & Science University, Portland, OR, USA; 3CareOregon,
Portland, OR, USA |
| PWM4 |
EVALUATION OF A PHARMACEUTICAL PATIENT ASSISTANCE PROGRAM: THE
NORPLANT REMOVAL PROGRAM
Joy KA, Petrilla AA, Klingman D, Hazard EH, Benjamin KL,
ValueMedics Research, LLC, Alexandria, VA, USA |
| |
Economic Outcomes Presentations |
|
|
| PWM5 |
FEASIBILITY OF SIMPLIFYING COMPLEX DECISION TREES VIA LINEAR
REGRESSION ANALYSIS: AN APPLICATION TO COST-EFFECTIVENESS ANALYSIS OF
HORMONE THERAPY FOR MENOPAUSAL SYMPTOMS
Botteman MF1, Wang Q1, Stephens JM1, Gao X1, Lian J2, 1Abt
Associates Clinical Trials, Bethesda, MD, USA; 2Pfizer Inc, New York,
NY, USA |
| PWM6 |
A
COMPARISON OF RESOURCE UTILIZATION FROM INPATIENT VERSUS OUTPATIENT
SURGERY: THE CASE OF LAPAROSCOPIC HYSTERECTOMY IN FLORIDA
Campbell ES, Florida A&M University, Tallahassee, FL, USA
|
| PWM7 |
ECONOMIC BURDEN OF OSTEOPOROSIS, BREAST CANCER, AND CARDIOVASCULAR
DISEASE AMONG WOMEN
Sasser A1, Birnbaum H1, Oster E1, Rousculp M2, 1Analysis
Group/Economics, Boston, MA, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA |
| PWM8 |
THE
LIFETIME MEDICAL COSTS OF WOMEN: CARDIOVASCULAR DISEASE, DIABETES, AND
STRESS URINARY INCONTINENCE
Birnbaum H, Leong S, Kabra A, Analysis Group/Economics, Boston,
MA, USA |
| PWM9 |
ECONOMIC IMPACT OF SILDENAFIL CITRATE ON A PHARMACY BUDGET
Cooke C1, Wong W2, Lee H3, Duttagupta S4, 1Pfizer Inc, Ellicott
City, MD, USA; 2CareFirst BlueCross BlueShield, Baltimore, MD, USA;
3University of Maryland School of Pharmacy, Ellicott City, MD, USA;
4Pfizer Inc, New York, NY, USA |
| PWM10 |
COST
OF ACCESS BY FORMULARY TYPE: A CASE STUDY OF SILDENAFIL CITRATE IN A
LARGE MANAGED CARE ORGANIZATION
Benson S1, Duttagupta S2, Poller L2, 1Pfizer Inc, Woodbury, MN,
USA; 2Pfizer Inc, New Yo | | | | | |
